Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Does Tau Truncation Sow Seeds of Aggregation?
1 June 2007. The microtubule-associated protein tau is a highly soluble protein that turns sticky in Alzheimer disease brain. Researchers have avidly studied the role of hyperphosphorylation in tau’s pathogenic conversion to neurofibrillary tangles, but other modifications have received less attention. Besides being phosphorylated, tau is proteolytically cleaved in neurons affected by AD, generating fragments that end up in tangles along with full-length tau. Those fragments could hold the key to tau aggregation, according to a new study from the labs of Eva-Maria and Eckhart Mandelkow at the Max Planck Unit for Structural Molecular Biology in Hamburg, Germany.

The presence of aggregation-prone, neurotoxic fragments of tau has previously been shown (Zilka et al., 2006; Hrnkova et al., 2007). A C-terminal truncation of tau by caspase-3 produces a fragment that promotes aggregation, and is present in AD brain (Gamblin et al., 2003).

The new results in the May 29 online PNAS show that tau is processed in cultured human cells to small fragments of the tau repeat region that then seed the aggregation of full-length protein. In vitro, the fragments induce tau to assume paired helical filament structure, a process that normally requires chemical enhancers of fibrillization. The results suggest that little snippets of the tau repeat domain may be a template for tangle formation, and raise the question of whether protease inhibitors could present a new approach to treating tauopathies.

In the study, first author Yipeng Wang and colleagues characterized the proteolysis and aggregation of tau in human N2a cells engineered for inducible tau expression, a model developed in the Mandelkow lab for studying tau aggregation and neurotoxicity (see ARF Paper Alert). Expression of a tau repeat domain fragment (specifically, the four-repeat isoform Q244-E372 with the FTDP17 mutation δK280) resulted in the appearance of three cleavage products. The protein was first clipped at the N-terminus by a thrombin-like protease and then underwent two more truncations at the C-terminus by an unknown activity. The N-terminal truncated fragment (F1) was soluble in the cells, while the shorter products (F2, F3) turned up in the sarcosyl centrifugation pellet as insoluble proteins along with the aggregated parent protein.

The production of C-terminal truncations (F2, F3) was required to see aggregation of the tau repeat fragment in the cells. When the researchers prevented N-terminal processing by mutating the cleavage site, tau was no longer processed at the N- or C-terminal, and there was no aggregation of the precursor.

Further, the scientists showed that expression of a short F3 fragment nucleates aggregation of coexpressed full-length wild-type tau, a form that does not normally aggregate. F3 also induced aggregation of the FTDP17 mutants δK280 and P301L. Thioflavin S staining and electron microscopy confirmed a paired helical filament structure. The aggregation was recapitulated in vitro, where F3 readily seeded the aggregation of full-length tau in solution into thioflavin-positive aggregates.

The researchers also looked at the role of phosphorylation. By analyzing phosphoepitopes in the expressed proteins, they found that repeat region sites were phosphorylated mainly in the soluble protein fraction, consistent with that modification inhibiting aggregation. Phosphorylation in the C-terminal PHF1 epitope was seen in both the soluble and aggregated full-length proteins, suggesting it may have a positive effect on aggregation. The ability of F3 to nucleate fibril formation of full-length tau will allow further studies on the effect of phosphorylation sites throughout the protein.

To look at the toxicity of tau, the investigators induced tau expression in cells and measured the release of lactate dehydrogenase (LDH) as an indicator of cell membrane dysfunction and cell death. In cells containing unaggregated forms of tau, no LDH was released, while expression of the F3 fragment led to both aggregation and LDH release. By simultaneously staining cells for tau aggregates and DNA fragmentation, the researchers revealed a correlation between the extent of aggregation and toxicity. This result is at odds with recent in-vivo work that shows cognitive defects in mice are unrelated to the presence of tau tangles (see ARF related news story), and the suggestion that other tau species are the toxic ones. Experiments aimed at manipulating tau proteolysis in vivo may shed some light on the potential pathological role of this new pathway to aggregation.—Pat McCaffrey.

Reference:
Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A. 2007 May 29; [Epub ahead of print] Abstract

 
Comments on News and Primary Papers
  Primary Papers: Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.

Comment by:  Troy Rohn
Submitted 1 June 2007  |  Permalink Posted 1 June 2007

This eloquent study examines the post-translational modification of tau. The authors used a previously developed model of tauopathy by expressing the mutant tau repeat domain first discovered in FTP with PD linked to chromosome 17 (FTDP17). Several points of this study bear mentioning: first, the authors demonstrate that proteolytically cleaved fragments enhance the aggregation of full-length tau, a finding that has been previously reported following the caspase-cleavage of tau (1,2). Intriguing about this new study is that the identity of the proteases involved in cleaving tau is not known. Although tau is a well-known substrate for caspases and calpains, the role of other potential proteases has not been investigated. It will be interesting to follow whether the identity of these potential proteases will be revealed and what exactly is their role during the progression of AD.

Another interesting finding of this study is the demonstration that aggregation of tau is modulated by phosphorylation but does not depend on it. One dilemma in this area of AD is how these two...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad